PTN Palatin Technologies Inc.

1.06
-0.03  -3%
Previous Close 1.09
Open 1.08
Price To Book 10.6
Market Cap 215247235
Shares 203,063,429
Volume 1,166,171
Short Ratio 17.09
Av. Daily Volume 979,828

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date extended to June 23, 2019.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Phase 2 trial to commence 1H 2019.
PL-3994
Heart failure
Phase 1 data released April 4, 2019 met endpoints.
PL-8177
Inflammatory bowel diseases

Latest News

  1. What Kind Of Share Price Volatility Should You Expect For Palatin Technologies, Inc. (NYSEMKT:PTN)?
  2. Palatin Technologies (PTN) in Focus: Stock Moves 5.7% Higher
  3. Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases
  4. The Palatin Technologies Share Price Has Gained 103%, So Why Not Pay It Some Attention?
  5. Analysis: Positioning to Benefit within Weatherford International, NiSource, Palatin Technologies, Astronics, MaxLinear, and FutureFuel — Research Highlights Growth, Revenue, and Consolidated Results
  6. Edited Transcript of PTN earnings conference call or presentation 12-Feb-19 4:00pm GMT
  7. Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update
  8. Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on February 12, 2019
  9. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
  10. Palatin Technologies, Inc. (PTN): Hedge Fund Sentiment Unchanged
  11. Edited Transcript of PTN earnings conference call or presentation 13-Nov-18 4:00pm GMT
  12. Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC — Emerging Consolidated Expectations, Analyst Ratings
  13. Here’s What Palatin Technologies Inc’s (NYSEMKT:PTN) P/E Ratio Is Telling Us
  14. What Kind Of Shareholders Own Palatin Technologies Inc (NYSEMKT:PTN)?
  15. Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update
  16. Why Palatin Technologies Inc (NYSEMKT:PTN) Looks Like A Quality Company
  17. Palatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist
  18. Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on November 13, 2018
  19. Earnings Preview: Palatin (PTN) Q1 Earnings Expected to Decline